Biofrontera AG (FRA:B8FK) FFO


FRA:B8FK Biofrontera AG FRA:B8FK
58 GF Score
Price €2.26
GF Value €2.29
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG FFO?

FFO (Funds from operations) only applies to REITs.

FRA:B8FK
58GF Score
Biofrontera AG FRA:B8FK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of €2.26 is trading 1.3% below its estimated GF Value™ of €2.29. GuruFocus considers Biofrontera AG to be Fairly Valued.

Key valuation signals for FRA:B8FK:

  • FFO:
  • GF Value™: €2.29 vs. price of €2.26 (1.3% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score

Get the complete analysis for FRA:B8FK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.26
Price
€2.29
GF Value